Research Triangle Park, NC - 7 September 2016. EpiCypher today announced its designation as Best University Startup by the National Council of Entrepreneurial Tech Transfer (NCET2), a group designated by the 114th United States Congress. EpiCypher will present to US Congress, investors and corporate partners at the inaugural University Startups “Demo Day” at the National Press Club in Washington, DC on September 20, 2016.
There are over 4,800 active university start-ups in the United States today. Those recognized as the Best University Startups 2016 are among the most exciting early-stage companies originating from the country’s top tier universities.
“We are delighted and honored to be named Best University StartUp at the inaugural Demo Day 2016 in Washington DC. EpiCypher has been built from the dedication and focus of our employees & Founders, support from our customers, and funding from Americas’ Seed Fund, the NIH SBIR program,” said Sam C. Tetlow, CEO, EpiCypher. “Our future is bright for both job creation and the rapid launch of new products and services. The fusion of these key elements enable us to realize our ultimate mission of saving human lives.
EpiCypher is a spinout from The University of North Carolina at Chapel Hill. Scientific Founders Drs. Brian Strahl, Vice-Chair (Department of Biochemistry & Biophysics at UNC-CH), Mark Bedford, Professor (MD Anderson Cancer Center), and Or Gozani, Professor (Stanford University) established the original scientific vision for the Company that remains today.
“To lead the world in the 21st Century, our nation must have a sustained commitment to education, scientific research, and startups,” says Tony Stanco, NCET2 executive director, “and American universities are uniquely positioned to deliver on all three to ensure the U.S. continues to lead socially and economically in this century, as it did in the last.”
EpiCypher Snaphot:
• 85 blue-chip customers
• 18 full-time employees; 80% with advanced degrees
• The only UNC-Chapel Hill spinout that is cash-flow positive (circa 2012)
• Doubled revenue annually for the past 3 years
About EpiCypher. EpiCypher is pioneering the science of epigenetics. Epigenetics is the conjunction of ‘epi’, Latin for above, and genetics. Epigenetics is an essential dimension of personalized medicine, representing additional biological coding beyond genetics that regulates protein expression. EpiCypher has brought necessary products to market, including the first biochemically pure recombinant nucleosome and the first industry-developed designer nucleosomes. In addition, EpiCypher is developing the first reliable epigenetics biomarker measurement system for use in research and clinical applications. EpiCypher has over 85 blue-chip customers, 18 people, and is cash-flow positive. For more information visit epicypher.com.
